Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

After Vertex President and CEO Reshma Kewalramani presented at the firm’s healthcare conference, JPMorgan analyst Jessica Fye notes that the ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...

Findings showed treatment with Alyftrek was noninferior to ELX/TEZ/IVA in absolute change from baseline in ppFEV1 at week 24 in both SKYLINE trials. In both trials, participants received oral ELX ...

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - ALYFTREK™ is approved for patients 6 years and older with at ...

In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and further decreased sweat chloride compared to TRIKAFTA ® - BOSTON, December 20, 2024--(BUSINESS WIRE)--Vertex ...

Vertex Pharmaceuticals has received FDA approval for Alyftrek in cystic fibroris, six years and older. The approval increases the company’s CF opportunity by around 6,000 patients at launch.

The FDA has approved Vertex’s Alyftrek, a once-daily triple combination for the treatment of cystic fibrosis in people 6 years and older who have mutations that are amenable to the therapy ...